April 2009
Volume 50, Issue 13
ARVO Annual Meeting Abstract  |   April 2009
INO-8875, An Adenosine A1 Agonist, in Development for Open-Angle Glaucoma Reduces IOP in Three Rabbit Models
Author Affiliations & Notes
  • N. Kim
    Inotek Pharmaceuticals, Lexington, Massachusetts
  • C. Crosson
    Medical University of South Carolina, Charleston, South Carolina
  • C. Supuran
    University of Florence, Florence, Italy
  • T. McCauley
    Inotek Pharmaceuticals, Lexington, Massachusetts
  • G. Southan
    Inotek Pharmaceuticals, Lexington, Massachusetts
  • R. Baumgartner
    Inotek Pharmaceuticals, Lexington, Massachusetts
  • W. McVicar
    Inotek Pharmaceuticals, Lexington, Massachusetts
  • Footnotes
    Commercial Relationships  N. Kim, Inotek Pharmaceucticals, E; C. Crosson, Inotek Pharmaceuticals, F; Inotek Pharmaceuticals, C; C. Supuran, Inotek Pharmaceuticals, F; T. McCauley, Inotek Pharmaceuticals, E; G. Southan, Inotek Pharmaceuticals, E; R. Baumgartner, Inotek Pharmaceuticals, E; W. McVicar, Inotek Pharmaceuticals, E.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 4061. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      N. Kim, C. Crosson, C. Supuran, T. McCauley, G. Southan, R. Baumgartner, W. McVicar; INO-8875, An Adenosine A1 Agonist, in Development for Open-Angle Glaucoma Reduces IOP in Three Rabbit Models. Invest. Ophthalmol. Vis. Sci. 2009;50(13):4061.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : INO-8875, an adenosine A1 receptor agonist, is under development for treatment of primary open-angle glaucoma. INO-8875 was evaluated for its pharmacology, efficacy and safety profile in animal models.

Methods: : In vitro receptor binding assays were used to characterize receptor selectivity of INO-8875. To evaluate in vivo efficacy, IOP responses and systemic blood levels were determined following topical administration of INO-8875 to Dutch-Belted (D-B) rabbits, and ocular normotensive and hypertensive New Zealand White (NZW) rabbits. To induce ocular hypertension, carbopol polymer (50 µL of 0.025%) was injected into the anterior chamber two weeks prior to drug administration. IOP was measured using a calibrated pneumotonometer. The preclinical safety profile of INO-8875 was determined in rabbits and dogs following once daily ocular dosing for 14 days.

Results: : Adenosine receptor-binding assays demonstrated that INO-8875 was highly selective to A1 receptors (Ki = 0.97 nM). In normotensive eyes of D-B and NZW rabbits, topical administration of INO-8875 (20 and 165 µg, respectively) produced significant lowering in IOP with a maximum reduction of 20 to 25% for approximately 6 hours. In ocular hypertensive eyes, administration of INO-8875 at a dose of 25 µg significantly lowered IOP by 20 to 30% from the baseline level at 1-hour, and sustained this effect throughout the 4-hour measurement time. Preclinical safety studies demonstrated that once daily ocular instillation for 14 days with INO-8875 (up to 2 mg/eye) was well-tolerated with no treatment-related ophthalmology and histopathology findings. Following ocular administration of INO-8875, systemic levels of INO-8875 were extremely low, suggesting that INO-8875 has the potential for a good therapeutic profile.

Conclusions: : INO-8875, a selective adenosine A1 agonist, is effective in lowering IOP and has a favorable safety profile in relevant nonclinical models.

Keywords: intraocular pressure • adenosine • drug toxicity/drug effects 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.